Genetic variant in the telomerase gene modifies cancer risk in lynch syndrome

European Journal of Human Genetics

Volumn 21, Issue 5, 2013, Pages 511-516

  Bellido, Fernando ^a   Guino, Elisabet ^b   Jagmohan Changur, Shantie ^c   Segui, Nuria ^a   Pineda, Marta ^a   Navarro, Matilde ^a   Lazaro, Conxi ^a   Blanco, Ignacio ^a   Vasen, Hans F A ^c   Moreno, Victor ^b,d   Capella, Gabriel ^a   Wijnen, Juul T ^c   Valle, Laura ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer risk modifier; Hereditary non polyposis colorectal cancer; HTERT; Lynch syndrome; Rs2075786; Telomerase

Indexed keywords

MISMATCH REPAIR PROTEIN; TELOMERASE;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE; TRANSCRIPTION INITIATION SITE;

ADULT; AGE FACTORS; BINDING SITES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPUTATIONAL BIOLOGY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINOID X RECEPTOR ALPHA; RISK FACTORS; SPAIN; TELOMERASE; TELOMERE;

EID: 84876681197     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.204     Document Type: Article

References (43)

1. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18.
2. Dunlop MG, Farrington SM, Carothers AD et al: Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6: 105-110. (Pubitemid 27033972)
3. Aaltonen LA, Salovaara R, Kristo P et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-1487. (Pubitemid 28226275)
4. DeFrancisco J, Grady WM: Diagnosis and management of hereditary non-polyposis colon cancer. Gastrointest Endosc 2003; 58: 390-408. (Pubitemid 38220239)
5. Quehenberger F, Vasen HF, van Houwelingen HC: Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005; 42: 491-496. (Pubitemid 40847237)
6. Jenkins MA, Baglietto L, Dowty JG et al: Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006; 4: 489-498.
7. Alarcon F, Lasset C, Carayol J et al: Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet 2007; 15: 831-836. (Pubitemid 47109041)
8. Choi YH, Cotterchio M, McKeown-Eyssen G et al: Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 2009; 7: 14.
9. Bonadona V, Bonaiti B, Olschwang S et al: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305: 2304-2310.
10. Antoniou AC, Chenevix-Trench G: Common genetic variants and cancer risk in Mendelian cancer syndromes. Curr Opin Genet Dev 2010; 20: 299-307.
11. Scott RJ, Lubinski J: Genetic epidemiology studies in hereditary non-polyposis colorectal cancer. Methods Mol Biol 2009; 472: 89-102.
12. Wijnen JT, Brohet RM, van Eijk R et al: Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology 2009; 136: 131-137.
13. Talseth-Palmer BA, Brenne IS, Ashton KA et al: Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome. J Med Genet 2010; 48: 279-284.
14. Houlle S, Charbonnier F, Houivet E et al: Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet 2011; 19: 887-892.
15. Londono-Vallejo JA: Telomere length heterogeneity and chromosome instability. Cancer Lett 2004; 212: 135-144. (Pubitemid 38997969)
16. Meeker AK, Hicks JL, Iacobuzio-Donahue CA et al: Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004; 10: 3317-3326. (Pubitemid 38685436)
17. Collins K, Mitchell JR: Telomerase in the human organism. Oncogene 2002; 21: 564-579. (Pubitemid 34146256)
18. Blasco MA, Lee HW, Hande MP et al: Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34. (Pubitemid 27431310)
19. Calado RT, Chen J: Telomerase: not just for the elongation of telomeres. Bioessays 2006; 28: 109-112.
20. McKay JD, Hung RJ, Gaborieau V et al: Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008; 40: 1404-1406.
21. Shete S, Hosking FJ, Robertson LB et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009; 41: 899-904.
22. Wrensch M, Jenkins RB, Chang JS et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009; 41: 905-908.
23. Jin G, Xu L, Shu Y et al: Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis 2009; 30: 987-990.
24. Landi MT, Chatterjee N, Yu K et al: A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009; 85: 679-691.
25. Rafnar T, Sulem P, Stacey SN et al: Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41: 221-227.
26. Petersen GM, Amundadottir L, Fuchs CS et al: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010; 42: 224-228.
27. Hofer P, Baierl A, Feik E et al: MNS16A tandem repeats minisatellite of human telomerase gene: a risk factor for colorectal cancer. Carcinogenesis 2011; 32: 866-871.
28. Hosgood 3rd HD, Cawthon R, He X, Chanock S, Lan Q: Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. Lung Cancer 2009; 66: 157-161.
29. Van Dyke AL, Cote ML, Wenzlaff AS et al: Chromosome 5p Region SNPs Are Associated with Risk of NSCLC among Women. J Cancer Epidemiol 2009; 2009: 242151.
30. Moreno V, Gemignani F, Landi S et al: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006; 12: 2101-2108.
31. Pros E, Gomez C, Martin T, Fabregas P, Serra E, Lazaro C: Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat 2008; 29: E173-E193.
32. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM: PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002; 18: 333-334. (Pubitemid 34183117)
33. Farre D, Roset R, Huerta M et al: Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res 2003; 31: 3651-3653. (Pubitemid 37442215)
34. Cawthon RM: Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009; 37: e21.
35. Mocellin S, Verdi D, Pooley KA et al: Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst 2012; 104: 840-854.
36. Ding Z, Green AG, Yang X, Chernenko G, Tang SC, Pater A: Retinoic acid inhibits telomerase activity and downregulates expression but does not affect splicing of hTERT: correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis/ multidrug-resistance model. Exp Cell Res 2002; 272: 185-191. (Pubitemid 34920686)
37. Pendino F, Dudognon C, Delhommeau F et al: Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene 2003; 22: 9142-9150. (Pubitemid 38067989)
38. Pickett HA, Baird DM, Hoff-Olsen P et al: Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene. Oncogene 2004; 23: 3434-3443. (Pubitemid 38669833)
39. Mendez-Bermudez A, Hills M, Pickett HA et al: Human telomeres that contain (CTAGGG)n repeats show replication dependent instability in somatic cells and the male germline. Nucleic Acids Res 2009; 37: 6225-6238.
40. Rampazzo E, Bertorelle R, Serra L et al: Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer 2010; 102: 1300-1305.
41. Mendez-Bermudez A, Royle NJ: Deficiency in DNA mismatch repair increases the rate of telomere shortening in normal human cells. Hum Mutat 2011; 32: 939-946.
42. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL: Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 2003; 15: 164-175. (Pubitemid 41582919)
43. Burn J, Gerdes AM, Macrae F et al: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.